Can we predict who can safely lower Anti-Rejection drugs after hand or face transplants?

NCT ID NCT02055521

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked for immune tolerance markers in 18 hand and face transplant recipients (transplanted at least one year prior). Researchers analyzed blood and skin biopsies to find a 'tolerance signature' that might identify patients who could safely reduce their lifelong anti-rejection medication. The goal is to minimize drug side effects while preventing graft rejection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors identify which transplant recipients can safely lower their anti-rejection drugs, reducing side effects.

What could go wrong

This is a small, observational study (18 people) looking for biological markers, not testing a new treatment. The markers may not reliably predict tolerance in hand or face transplants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAND AND FACE ALLOTRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospices Civils de Lyon

    Lyon, 69003, France